Pancreatic Cancer Research

ResearcherHospital of the University of PennsylvaniaActive in the last 2 years

Susan M. Domchek

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5914-7272; OpenAlex author ID A5063299870, A5108096308. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 2, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers, 1 trial · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 15

  1. Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Tria… Co-author DOI 10.1001/jamaoncol.2026.0870↗
  2. Assessment of barriers to pancreatic cancer surveillance in high-risk individuals. Co-author DOI 10.1002/jgc4.70117↗
  3. Integration of Germline Genetic Testing Into Routine Clinical Practice for Patients With Pancreatic Adenocarcinoma. Last author DOI 10.1200/op.24.00356↗
  4. Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival. Co-author DOI 10.1001/jamanetworkopen.2023.45013↗
  5. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Ruca… Co-author DOI 10.1158/1078-0432.ccr-23-1467↗
  6. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Co-author DOI 10.1016/s1470-2045(22)00369-2↗
  7. Reaching beyond family history as inclusion criteria for pancreatic cancer surveillance in high-risk populations. First author DOI 10.18632/genesandcancer.223↗
  8. Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations. Co-author DOI 10.1093/jncics/pkaa121↗
  9. EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer. Co-author DOI 10.1158/1940-6207.capr-21-0161↗
  10. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, B… Last author DOI 10.1200/jco.21.00003↗
  11. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Co-author DOI 10.1038/s41416-019-0582-7↗
  12. Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation. Co-author DOI 10.1200/po.18.00271↗
  13. Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. Last author DOI 10.1200/po.17.00152↗
  14. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. Last author DOI 10.1200/po.17.00316↗
  15. PALB2 mutations in familial breast and pancreatic cancer. First author DOI 10.1007/s10689-011-9426-1↗

Trials 1

  1. INO 5401 Vaccination in BRCA1/2 Mutation Carriers Principal investigator NCT04367675↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kim A. Reiss · 10 shared papers, 2018–2026 · strength 1.53
  2. Katherine L. Nathanson · 9 shared papers, 2011–2026 · strength 1.27
  3. Mark H. O’Hara · 5 shared papers, 2019–2026 · strength 0.72
  4. Robert H. Vonderheide · 4 shared papers, 2018–2026 · strength 0.55
  5. Bryson W. Katona · 3 shared papers, 2021–2025 · strength 0.55
  6. Zain M. Hannan · 3 shared papers, 2021–2026 · strength 0.51
  7. Shun Yu · 4 shared papers, 2018–2021 · strength 0.46
  8. Ronac Mamtani · 3 shared papers, 2019–2023 · strength 0.46
  9. Thomas Benjamin Karasic · 3 shared papers, 2021–2023 · strength 0.40
  10. Timothy J. Brown · 2 shared papers, 2023–2026 · strength 0.39
  11. Erica L. Carpenter · 2 shared papers, 2021–2023 · strength 0.26
  12. Kelsey S. Lau‐Min · 1 shared paper, 2025 · strength 0.23
  13. Louise L. Wang · 1 shared paper, 2022 · strength 0.22
  14. Grace Snyder · 1 shared paper, 2025 · strength 0.22
  15. Max Miller Wattenberg · 2 shared papers, 2020–2021 · strength 0.22
  16. Gregory Lawrence Beatty · 2 shared papers, 2020–2021 · strength 0.22
  17. Talia Golan · 1 shared paper, 2023 · strength 0.20
  18. Ben Boursi · 1 shared paper, 2023 · strength 0.20
  19. Peter James O'Dwyer · 2 shared papers, 2019–2020 · strength 0.20
  20. Jacob Edward Till · 1 shared paper, 2023 · strength 0.16
  21. Mark Alan Rosen · 1 shared paper, 2020 · strength 0.11
  22. Koushik K. Das · 1 shared paper, 2021 · strength 0.10
  23. Anil K. Rustgi · 1 shared paper, 2021 · strength 0.10
  24. Parul Agarwal · 1 shared paper, 2019 · strength 0.09
  25. Rachna T. Shroff · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.